Raymond James & Associates Bio Line Rx Ltd. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding BLRX
# of Institutions
36Shares Held
2.83MCall Options Held
75.1KPut Options Held
5.1K-
Highbridge Capital Management LLC New York, NY1.01MShares$3.43 Million0.05% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.77 Million4.05% of portfolio
-
Values First Advisors, Inc.166KShares$565,9260.02% of portfolio
-
Atria Wealth Solutions, Inc. New York, NY94.1KShares$320,0520.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC92KShares$312,8000.0% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $209M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...